- Home
- NUWE vs CMND Comparison
NUWE vs CMND Comparison
Compare NUWE & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NUWE | CMND |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | United States | Canada |
| Employees | 38 | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7M | 1.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NUWE | CMND |
|---|---|---|
| Price | $1.17 | $0.73 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 31.9K | ★ 6.6M |
| Earning Date | 05-05-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.14 | N/A |
| Revenue Next Year | $18.51 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.19 | $0.07 |
| 52 Week High | $25.95 | $3.25 |
Technical Indicators
Market Signals| Indicator | NUWE | CMND |
|---|---|---|
| Relative Strength Index (RSI) | 39.77 | 43.19 |
| Support Level | $0.96 | $0.59 |
| Resistance Level | $1.19 | $1.18 |
| Average True Range (ATR) | 0.08 | 0.18 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 14.29 | 15.99 |
Price Performance
Historical ComparisonAbout NUWE Nuwellis Inc.
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.
About CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.